Patients with a history or presence of significant ventricular or atrial tachyarrhythmia are excluded History or presence of clinically significant ventricular or atrial dysrhythmia > grade (National Cancer Institute [NCI] CTCAE version . [v.])\r\n* Patients with chronic, rate-controlled atrial arrhythmias who do not have other cardiac abnormalities are eligible History or presence of clinically significant ventricular or atrial dysrhythmia >Grade per NCI CTCAE v. History or presence of clinically significant ventricular arrhythmias, atrial fibrillation, resting bradycardia, or conduction abnormality History or presence of clinically significant ventricular arrhythmias, atrial fibrillation, resting bradycardia, or conduction abnormality History or presence of clinically significant ventricular or atrial tachyarrhythmias, or cardiac arrest Presence of unstable atrial fibrillation (ventricular response > beats per minute) Presence of any of the following on electrocardiogram (ECG):\r\n* Atrial arrhythmias, including atrial fibrillation and flutter\r\n* Atrioventricular (AV) block\r\n* Heart rate < beats/minute unless the participant is otherwise eligible, without significant cardiac concerns and approval is obtained by the protocol chair/study cardiologist prior to enrollment\r\n* Heart rate > beats/minute\r\n* Ventricular fibrillation\r\n* Ventricular tachycardia\r\n* Premature ventricular contractions\r\n* Wolff-Parkinson-White syndrome\r\n* NOTE: any questions on cardiac eligibility should be reviewed by the Study Cardiologist for approval in advance of enrollment History of or presence of clinically significant ventricular or atrial tachyarrhythmias History or presence of sustained ventricular tachyarrhythmia; (patients with a history of atrial arrhythmia are eligible but should be discussed with Novartis prior to enrollment) History of or presence of clinically significant ventricular or atrial tachyarrhythmias History or presence of sustained ventricular tachyarrhythmia (patients with a history of atrial arrhythmia are eligible but should be discussed with the study principal investigator [PI] prior to enrollment) Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs, or electrocardiographic (ECG) examination (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular rate is controlled) that precludes continuation or initiation of treatment with NEOD or participation in the study Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs, or electrocardiogram (ECG) examination (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular rate is controlled) that precludes continued or initiation of treatment with NEOD or participation in the study Patients have impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) history or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation; b) clinically significant resting bradycardia (< beats per minute); c) left ventricular ejection fraction (LVEF) assessed by -dimensional (D) echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) < %; d) pericardial effusion History or presence of sustained ventricular tachyarrhythmia (patients with a history of atrial arrhythmia are eligible but should be discussed with the Novartis prior to enrollment) History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the study chair prior to enrollment). History or presence of ventricular tachyarrhythmia Donor must have adequate cardiac function with no history of congestive heart failure and no history of atrial fibrillation or ventricular tachyarrhythmia. History or presence of ventricular tachyarrhythmia Presence of unstable atrial fibrillation (ventricular response > bpm History of or presence of clinically significant ventricular or atrial tachyarrhythmias